SeaStar Medical Holding Corp
NASDAQ:ICU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
SeaStar Medical Holding Corp
Inventory
SeaStar Medical Holding Corp
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SeaStar Medical Holding Corp
NASDAQ:ICU
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Inventory
$2.9B
|
CAGR 3-Years
16%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Inventory
$1.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
13%
|
|
|
Stryker Corp
NYSE:SYK
|
Inventory
$5.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
12%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Inventory
$6.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
10%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Inventory
$1.8B
|
CAGR 3-Years
27%
|
CAGR 5-Years
25%
|
CAGR 10-Years
27%
|
|
SeaStar Medical Holding Corp
Glance View
Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company is headquartered in Tampa, Florida. The company went IPO on 2021-01-26. The firm is focused on redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. The firm's technologies rely on science to provide life-saving solutions to critically ill patients. The firm is engaged in developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
